Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

TESTING LABS APPEAR TO HAVE BEST CHANCE FOR RECOGNITION AS THIRD-PARTY REVIEWERS UNDER FDA PILOT, LEVITT SAYS; INDUSTRY QUESTIONS LABS' EXPERTISE

This article was originally published in The Gray Sheet

Executive Summary

Identification of third-party reviewer organizations that offer both expertise in device regulation and independence from manufacturers could prove to be a key challenge to FDA in implementing its third-party review pilot program. At two FDA events held during the week of April 15, agency officials emphasized the importance of third-party independence while industry reps stressed the need for outside groups with considerable device experience.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT005841

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel